doctorate in molecular oncology from the University of Munich (LMU) and went to medical school at the University of Wurzburg. Prior to founding APG, he assessed scientific licensing-in opportunities for Mundipharma (part of Purdue Pharma). He has worked in medical affairs at Janssen Cilag, Teva and Novartis. His academic research focus was in multiple sclerosis in the Cantonal Hospital of Saint Gall and schizophrenia at the University Hospital Basel, Switzerland. He was a principal investigator in several clinical studies. He is a neurologist with a research focus in CNS indications. Specifically, he is interested in neurodegenerative diseases and oncology.
publication list email@example.com
Dr. Eric Culbert
He is consulting Avergen on drug discovery processes. He is currently the CEO of a biotech company in England. He held previously leadership roles in AstraZeneca Pharmaceuticals, Cambridge Antibody Technology, and MedImmune Inc. Formerly CEO of Blink Therapeutics Ltd. Expert in project evaluation, preclinical development, translational medicine/biomarkers and target product profiles.
Dr. Sarah Arbe-Barnes
Director of Translational and Clinical Science
Expert in market access, reimbursement, translational medicine, product approval programs, overseeing clinical and non clinical project design and candidate selection. Previously, she held leadership roles in Covance and a number of European biopharma companies.
Dr. Peter Sennhenn
Medicinal Chemistry Expert
With a strong background in synthetic organic chemistry and over 20 years of drug discovery experience in leading functions in big pharma, biotech and CRO companies.